TY - JOUR
T1 - Human mesenchymal stem cells improve myocardial performance in a splenectomized rat model of chronic myocardial infarction
AU - Liu, Jen-Fang
AU - Wang, Bao Wei
AU - Hung, Huei Fong
AU - Chang, Hang
AU - Shyu, Kou-Gi
N1 - Funding Information:
This study was sponsored in part by a grant from the National Science Council, Taipei, Taiwan.
PY - 2008/2
Y1 - 2008/2
N2 - Background/Purpose: Cellular therapy has been applied to animal studies and clinical trials for acute or subacute myocardial infarction. Little is known about the effect of cell therapy on chronic myocardial infarction. The goal of this study was to investigate myocardial performance after human bone marrow-derived mesenchymal stem cell (hMSCs) transplantation in rats with chronic myocardial infarction. Methods: The hMSCs were obtained from adult human bone marrow and expanded in vitro. The purity and characteristics of hMSCs were identified by flow cytometry and immunophenotyping. Splenectomy in male rats was performed to prevent immune reaction. One week after splenectomy, ligation of the left anterior descending coronary artery was performed to induce myocardial infarction. Four weeks after ligation of the coronary artery, culture-expanded hMSCs were injected intramyocardially at the left anterior free wall. Left ventricular function measured by echocardiogiaphy, infarct size and immunohistochemical stain were performed to evaluate the effect of the therapy. Results: The engrafted hMSCs were positive for the cardiac marker troponin T. Infarct size (35.4 ± 3.4% vs. 53.3 ± 3.0%, p
AB - Background/Purpose: Cellular therapy has been applied to animal studies and clinical trials for acute or subacute myocardial infarction. Little is known about the effect of cell therapy on chronic myocardial infarction. The goal of this study was to investigate myocardial performance after human bone marrow-derived mesenchymal stem cell (hMSCs) transplantation in rats with chronic myocardial infarction. Methods: The hMSCs were obtained from adult human bone marrow and expanded in vitro. The purity and characteristics of hMSCs were identified by flow cytometry and immunophenotyping. Splenectomy in male rats was performed to prevent immune reaction. One week after splenectomy, ligation of the left anterior descending coronary artery was performed to induce myocardial infarction. Four weeks after ligation of the coronary artery, culture-expanded hMSCs were injected intramyocardially at the left anterior free wall. Left ventricular function measured by echocardiogiaphy, infarct size and immunohistochemical stain were performed to evaluate the effect of the therapy. Results: The engrafted hMSCs were positive for the cardiac marker troponin T. Infarct size (35.4 ± 3.4% vs. 53.3 ± 3.0%, p
KW - Cellular therapy
KW - Mesenchymal stem cells
KW - Myocardial infarction
KW - Myocardial regeneration
UR - http://www.scopus.com/inward/record.url?scp=40749091694&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=40749091694&partnerID=8YFLogxK
U2 - 10.1016/S0929-6646(08)60130-8
DO - 10.1016/S0929-6646(08)60130-8
M3 - Article
C2 - 18285249
AN - SCOPUS:40749091694
SN - 0929-6646
VL - 107
SP - 165
EP - 174
JO - Journal of the Formosan Medical Association
JF - Journal of the Formosan Medical Association
IS - 2
ER -